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Abstract: 
Background: Buprenorphine‟s availability in primary care settings offers increased access 
to treatment and linkage to primary care for opioid-dependent patients. Currently, 
tuberculin skin testing (TST) is recommended for patients enrolling in methadone 
maintenance treatment (MMT), but not for those enrolling in buprenorphine maintenance 
treatment (BMT).  
Objectives: To compare TST screening results in enrollees in BMT and MMT programs 
and assess the correlates of TST positivity among these subjects.  
Methods: A cross-sectional analysis of a retrospective cohort study was conducted to 
compare concurrent TST results among contemporaneously matched groups of MMT and 
BMT patients in the same community.  
Results: TST positivity was 9% in both MMT and BMT settings (p = .27). Increased TST 
positivity was associated with being Black (AOR = 3.53, CI = 1.28–9.77), Hispanic 
(AOR = 3.11, CI = 1.12–8.60), and having higher education (AOR= 3.01, CI = 1.20–
7.53).  
Conclusions: These results confirm a similarly high prevalence of TST positivity in 
opioid-dependent patients enrolling in MMT and BMT programs. Racial and ethnic 
health disparities remain associated with TST positivity, yet a relationship between 
higher education and tuberculosis requires further investigation.  
Scientific significance: These data suggest the importance of incorporating TST screening 
in emerging BMT programs as a mechanism to provide increased detection and treatment 
of tuberculosis infection in opioid-dependent patient populations




“Drug addiction,” or more formally “substance dependence” as termed by the American 
Psychiatric Association, is defined as a “maladaptive pattern of substance use leading to 
clinically significant impairment or distress, as manifested by three (or more) of the 
following, occurring any time in the same 12-month period: tolerance; withdrawal; 
increasing use (quantity and/or frequency) over time; persistent but unsuccessful 
intention to cut down on use; significant time occupied by habit; social, occupational and 
recreational activities suffer as a result; and/or usage is continued in spite of recognition 
of deleterious physical or psychological effects [1]. 
In the United States today it is estimated that approximately 2 million (range between 1.5 
and 2.4 million) people are dependent upon opiate-containing substances [2, 3].  In 
addition to heroin, opioids of abuse range from natural opium to manufactured forms 
including codeine, fentanyl, hydrocodone, methadone, morphine, and oxycodone.  
Natural opium has been used recreationally for over five thousand years with Sumerian 
records of a “joy plant” dating back to ancient Mesopotamia in 3400 B.C. [4].  Since the 
Sumerians, opioids have been used continuously, both recreationally and clinically, in 
cultures around the world.  Opioids can be taken through intravenous, intranasal or 
inhalation routes of administration and are regularly used for many clinical indications in 
addition to their potential for abuse.   
Of the approximate 2 million opiate-dependent persons in the United States presently, 
approximately 900,000 are dependent on heroin [5].  Irrespective of the opiate or 
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administrative route of choice, opiate dependence is a significant problem in the United 
States today with enormous social and economic costs to society [6].  A National Institute 
of Justice study reported that over 60% of inmates in federal prisons in 2002 were 
incarcerated for crimes associated with illicit substances trade or usage [7].  In addition to 
the challenges posed in the legal and social realms by substance abuse, the financial costs 
are substantial: a 1994 study suggested that in New York City alone substance abuse cost 
tax payers over 20 billion dollars [8].  Since 1994 the number of substance users has 
increased, as has the cost. While the socioeconomic challenges associated with substance 
dependence are notable, they are, however, outside the scope of this paper.  In this report 
we will discuss in greater detail specific concerns surrounding the implementation of 
substance dependence treatment programs and the policy implications necessary to 
optimize treatment for this marginalized population. 
Health status of substance users 
Substance dependence has significant impact on the health status of substance-dependent 
patients, including higher rates of infectious diseases, medical comorbidities, and mental 
illness [9-14].  
Epidemiologically, individuals who use illicit substances, and particularly opioids, are at 
increased age-matched risk for associated infectious diseases.  For example, many studies 
have shown substance users to have higher rates of human immunodeficiency virus 
(HIV)[10, 15].  While many opioids are used by patients with HIV, those that are 
injectable have contributed most to the transmission of HIV through needle-sharing 
practices involving blood-to-blood contact [5].  Currently, over one in three cases of 
HIV/AIDS in the United States are accounted for by injecting drug users (IDUs) or their 
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partners or children, and approximately 25% of new HIV cases annually in the United 
States are secondary to injecting drug use practices [10, 15].  In addition to high rates of 
HIV/AIDS, higher rates of tuberculosis have also been documented in this population, 
with both increased risk of Mycobacterium tuberculosis infection and tuberculosis 
disease [11, 16].  Increased risk for tuberculosis is due in part to the fact that it is a 
common opportunistic infection associated with HIV, and further that HIV markedly 
increases reactivation of latent tuberculosis infections [17].  Higher rates of tuberculosis 
are additionally caused by the impoverished and cramped living conditions many 
substance users live in; such living quarters can increase the risk of air-borne 
transmission of Mycobacterium tuberculosis causing infection and leading to disease 
[11].  Similarly, other research has shown that rates of viral hepatitis are increased in 
populations who use opioids through intravenous routes [12, 18].  There is a higher risk 
for transmission of both hepatitis B and hepatitis C viruses through blood-to-blood 
contact which frequently occurs through needle sharing in injecting drug use.  
Additionally, many patients who contract one form of viral hepatitis via intravenous drug 
abuse are co-infected with both hepatitis B and C, with some studies showing over 80% 
co-infection rates in this population [19]. 
In addition to the increased risk of infectious diseases, this population is also 
disproportionately affected by mental illness.  Research demonstrates that mental 
illnesses such as depression, schizophrenia and bipolar disorder are increased in this 
population and can lead to higher risk-taking behavior, including substance use, injecting 
drug use, and high-risk sexual practices that may expose persons to sexually transmitted 
infections including HIV [13, 20]. 
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Marginalization from health services 
This disparity in general health status amongst substance users, and specifically those 
who use intravenous drugs, has been well documented yet remains largely unaddressed.  
In part, poor health status is due to a significant marginalization of these individuals from 
mainstream healthcare resources [21, 22].  This marginalization is multi-factorial, 
however in part occurs due to stigma against substance users both from the general public 
as well as health care providers [23, 24].  Despite significant evidence illustrating the 
benefits of substance abuse treatment modalities such as methadone [25], many health 
care practitioners continue to be uncomfortable treating active substance users. One study 
of primary care practitioners in New York City treating HIV patients revealed 55% were 
uncomfortable providing services to patients injecting drugs [26].  Other clinicians may 
be comfortable working with substance users however are wary of long-term 
maintenance treatment approaches (i.e. medication-assisted treatment – further discussed 
below) [27].  In the latter case, while care may be provided, it is frequently sub-optimal 
as the doctor-patient relationship is compromised by a lack of trust between parties and 
discomfort on the part of the clinician in dealing with this population [28].   
Whether clinicians do or do not provide services to this population, in both cases 
practitioners often maintain that substance dependence is different from other diseases 
and understand substance dependency as a personal choice, and accordingly not a 
responsibility of the public health care system.  The New York Academy of Medicine 
discusses how, “…much of the general public and those in the health care field have 
come to believe that drug dependence is essentially self-indulgent, voluntary behavior for 
which individuals should take personal responsibility [28].”  Consequently public opinion 
Page | 9  
 
frequently maintains that substance dependence should be dealt with politically (i.e. 
keeping illicit substances off the street) and/or legally (i.e. punishing those who 
participate in the trade or use of such substances), but not medically.  In parallel, there is 
reticence amongst health care providers to offer treatment to substance users as 
discussed.  Furthermore, for some clinicians who do provide treatment to this population 
there is a harsher approach to medication non-compliance given the view that substance 
dependence is a fundamentally different type of disease than other chronic illnesses such 
as diabetes or HIV [29-32].   
These perceptions are in contrast to a significant body of literature which understands 
substance dependence as a chronic illness influenced by biological, psychological and 
socioeconomic factors, not unlike other chronic illnesses such as HIV or diabetes.  
Multiple previous studies – including twin studies, cohort studies, and randomized 
control trials – have lead science to now purport that substance dependence must be 
conceptualized and treated as a non-curable, chronic disease.  Twin studies have shown 
that there is a significant genetic component to substance dependence [33-35].  
Additionally, we now know that there are typical neurostructural and neurochemical 
responses to substance use and dependence underlining the pathophysiologic nature of 
dependence [36, 37].  Finally, we know that social problems such as poverty, poor social 
support structures, or psychiatric co-morbidities portend a poor outcome of treatment 
with frequent non-compliance to treatment plans and relapse following discharge [38, 
39].  While none of this evidence is sufficient to state that substance dependence is by 
definition a chronic illness, when held up against well-established literature of other 
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chronic diseases such as asthma, hypertension, or diabetes, there is a striking similarity 
between the etiology and correlates of treatment success [28].    
More specifically, several key challenges exist in working with this population that 
complicate the ability of clinicians to provide effective and/or compassionate care. Due to 
an often chaotic set of life circumstances, many substance users have significant 
difficulty interacting with the health care system in a traditional fashion. For instance, 
many patients in this population have difficulty keeping set appointment times required at 
most health facilities and therefore frequently utilize emergency departments or drop-in 
clinics as a replacement for general primary care centers [40-43].  Secondly, high 
psychiatric co-morbidities can make these patients challenging and often frustrating to 
deal with [28].  The same mental illness burden also leads to challenges for such patients 
in accessing reliable and consistent primary care [13].  Finally, there is a dearth of 
effective medical and psychosocial outreach programs engaging this population to enter 
treatment in the traditional fashion, further exacerbating the tendency of this population 
to visit emergency departments with late-stage disease rather than accessing primary care 
services on a regular basis [44]. 
However, aside from the multiple factors making this population less likely to regularly 
access health resources, and irrespective of whether substance dependence should in fact 
be examined through the lens of a chronic illness, current public opinion, including that 
of many health care workers, has not yet adopted this perspective.  This has lead to an 
increasing and continued stigmatization of this population which has only exacerbated 
the difficulty in effectively providing health services to such patients.  In particular, it has 
lead to a lack of primary care practitioners willing to provide services for these patients, 
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and additionally has created an even greater perceived lack of health services given the 
dearth of information readily available to this population.   
Medication-assisted treatment 
Medication-assisted treatment, or a therapeutic modality for substance dependence in 
which medications are used in parallel with behavioral therapy, is the most effective 
treatment strategy in this population [45, 46]. Furthermore, it is an important strategy to 
address parallel and comorbid health issues for substance-dependent patients. 
Medications such as methadone and buprenorphine – further described below – have 
been shown to provide several key benefits to this population. Primarily, these 
medications, especially when paired with behavioral therapeutic approaches are the most 
effective modality to address substance dependence [45, 46]. Secondarily, medication-
assisted treatment modalities have been demonstrated as effective means to engage 
patients in treatment for associated conditions, including infectious diseases, mental 
health, and/or non-substance-dependence related medical comorbidities. A third critical 
benefit of medication-assisted treatment is that, in addition to acting as a foundation for 
increased patient health services engagement, it enhances adherence to treatments for 
associated conditions, including for instance, HIV and tuberculosis [45-48]. In this paper 
we will primarily discuss the two most effective medication-assisted treatments, 
methadone and buprenorphine. 
Methadone: medication-assisted treatment for substance dependence 
Methadone is a synthetic, full mu-opioid agonist, originally developed in 1939 in 
Germany in an effort to identify alternative opiates due to a nation-wide opium shortage.  
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In 1947 it was introduced in the United States by Eli Lily as an analgesic medication 
under the name of Dolophine.  Since then it has become more well-known for its ability 
to treat opiate dependence when used as an opiate substitution therapy, or, a “medication-
assisted treatment.”  In 1964 Vincent Dole and Marie Nyswander of Rockefeller 
University, first pioneered the use of methadone to treat heroin addiction.  They initially 
treated 22 patients using methadone and were able to successfully show that patients 
treated with methadone in combination with psychosocial interventions stopped heroin 
usage and regained self-confidence and an ability to live typical family and work lives 
[49].  This study laid the foundation for the usage of methadone as a medication-assisted 
treatment; Dole later received the Lasker award for this work. 
Since the 1960s the usage of methadone for opiate dependence has become much more 
well refined with methadone maintenance therapy now offered in outpatient settings 
throughout the world [24, 25].  Methadone maintenance treatment is a medication-
assisted treatment and therefore patients typically take methadone for long, if not 
indefinite, periods of time following opiate dependence.  In treatment programs patients 
receive daily doses under the regular supervision of a certified doctor with doses ranging 
significantly depending upon the individual.  In the United States most programs initiate 
patients on a low dose and gradually increase daily dosage until symptoms of withdrawal 
and cravings for opiate use are well controlled.  For most programs, patients are initially 
required to visit a clinic daily to receive their treatment.  However, following a certain 
period of time – location and provider-dependent, and pending continued compliance and 
negative drug screening tests – patients are allowed to visit the clinic less frequently, 
taking some of their doses independently at home.   
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With now over 40 years of research examining the impact of methadone maintenance 
treatment there is evidence of multiple benefits resulting from treatment programs.  First, 
methadone can successfully manage opiate dependence, especially when paired with 
additional psychosocial interventions [24, 25, 50].  Secondly, methadone programs have 
been shown to be a cost-effective intervention when examining their impact on public 
health as well as societal economic and financial statistics [51].  Methadone has also been 
shown to have ancillary beneficial effects including: reducing rates of prison recidivism 
[52]; decreasing transmission of infectious diseases including HIV, tuberculosis and viral 
hepatitis [53]; improving clinical compliance and treatment outcomes for chronic 
illnesses [30, 54]; enhancing general employment status and opportunities [55]; 
decreasing high-risk behaviors such as needle sharing and injecting [56] as well as 
overdoses from opiate abuse [57]; and, generally improving psychological and physical 
health status for patients enrolled in treatment programs [58].  
Regulation of methadone treatment 
Despite research demonstrating the marked benefits of methadone maintenance 
treatment, however, it remains a controversial issue, and access to methadone treatment is 
available in only a limited capacity due to stringent legal and clinical regulations for use.  
A brief discussion of the history of regulations surrounding methadone and other opiate-
replacement therapies is instructive to understanding the current policy debates 
surrounding newer treatment modalities. 
Prior to Dole and Nyswander‟s seminal work with methadone at Rockefeller in the early 
1960s, prescribing opiates to opioid-dependent patients in the United States was difficult, 
if not impossible. In 1914 the Harrison Act along with a group of passionate anti-opioid 
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politicians began to limit the ability of clinicians to prescribe opiates to this population. 
In 1920, when the American Medical Association similarly condemned the practice, 
clinicians began to be formally prosecuted for offering opiate-replacement therapies. 
During much of this period Harry Anslinger was head of the Bureau of Narcotics –  
Ansligner purported that severe penalties for possession, use or sale of illicit substances 
would ultimately eliminate substance dependence. Similarly, he was not in favor of 
opiate-replacement therapies and lead efforts to stop clinicians from engaging in such 
practices [32]. 
Data from the Rockefeller studies came out in the setting of a harsh legal environment for 
substance users as well as the clinicians that aimed to treat them, however also at a time 
when sentiment for the treatment and “rehabilitation” of opiate-dependent patients was 
on the rise [59, 60].  Following Dole and Nyswander‟s data, multiple treatment centers 
sprang up throughout the country functioning mainly through Investigational New Drug 
(IND) certifications issued by the Food and Drug Administration.  IND certification was 
important as it allowed centers to provide treatment in spite of the Bureau of Narcotics 
continued opinion that providing opiates to substance-dependent patients was illegal.  
While thousands of patients were enrolled in treatment in the first 10 years [2], 
government agencies maintained their opposition to the programs and many activist and 
patients-rights groups derided the practice as an inappropriate approach to the treatment 
of substance abuse [61].  During this time the FDA refused to qualify methadone as a 
legitimate form of therapy, thereby limiting the number of programs functioning under 
the label of “research.”  These limitations quickly lead to many opiate-dependent patients 
(largely heroin) being unable to enroll in treatment and generated long waiting lists for 
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programs [32].  In 1973 new Federal regulations were approved, and while originally 
intended to be revised regularly, between approval and 2001, were only amended twice.  
Most notably in the 1973 revisions was included the implementation of a physician 
accreditation process for the prescription of methadone.  In 1974, Congress approved 
further oversight mechanisms for methadone treatment programs, placing much of the 
jurisdiction under the DEA [62].     
Between the 1920s and 2003 the number of patients receiving methadone has increased 
from approximately 20,000 to 180,000; still only a significant minority of the opiate-
dependent population in the United States.  Throughout this time period efforts were 
made to revise and ease the FDA regulations however significant resistance was voiced 
by both the DEA as well as clinicians offering treatment [32].  Ultimately, while opinions 
are diverse, the regulatory environment during the 1970s, 80s, and 90s has largely been 
credited with limiting access to methadone treatment. 
Buprenorphine – a new medication-assisted treatment 
Buprenorphine is a partial-opiate agonist that was first noted to have potential clinical 
utility in 1978 [63].  At the time, buprenorphine was particularly interesting due to its 
potential to limit the adverse side effects associated with methadone toxicity in opiate-
naïve individuals.  Potential clinical use for substance dependence, and evidence for 
limited toxicity, was formally illustrated by the early 1990s [64-66].  In addition to data 
suggesting that buprenorphine could be an effective clinical treatment for opioid-
dependence, the limited toxicity (due to its partial agonist properties and formulation) 
significantly decreased concerns for diversion of the medication as it largely limited the 
potential for overdoses seen frequently with methadone.  This lead many clinicians and 
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scientists to believe that following FDA approval for the clinical use of buprenorphine, it 
might be exempted from many of the severe regulatory constraints that limited 
methadone treatment access.   
Due in large part to the efforts of private pharmaceutical company Reckitt and Colman – 
who decided to market buprenorphine and in doing so take on the legal and political 
bureaucracy involved in the regulation of methadone – and accompanied by several key 
political allies, legislation was developed to ease the previous regulations for opiate-
replacement therapies.  The political lobbying was done with the express intention of 
establishing the legal framework necessary to expand the potential patient population for 
buprenorphine prior to Reckitt and Colman bringing the drug to market.  Beginning in 
1995, the legislation of the proposed Drug Addiction Treatment Act (DATA) – a rather 
minor amendment to the existing legislation – took more than 5 years to finally be passed 
by Congress.  In 2000, President Clinton signed into law the DATA which offered 
clinicians the opportunity to obtain special training which would exempt them from 
obtaining DEA certification as well as allow them to offer buprenorphine treatment 
outside of federal methadone regulations [32].  
On October 8
th
, 2002 buprenorphine was approved for the treatment of opiate-
dependence making it the third such drug to gain certification (LAAM – levo-alpha-
acetyl methadol, a similar compound to methadone – had been previously approved in 
1993 by the FDA however was subsequently removed from both the European and US 
markets in 2001 and 2003 respectively).  Buprenorphine is a partial opioid agonist at the 
mu-opioid receptor and an antagonist at the kappa-opioid receptor [63].  As a result, 
buprenorphine blocks patients‟ ability to use exogenous opioids while at the same time 
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preventing withdrawal symptoms.  Similarly, buprenorphine has a lesser potential for 
abuse or overdose and therefore risks of diversion are of less concern than those for 
methadone [66].  Because of these pharmacological properties, buprenorphine has been 
classified as a Schedule III medication whereas methadone is a Schedule II; this will 
enable its wider use clinically and aid in eliminating stringent regulatory barriers seen 
with methadone.   
Previous research has shown that buprenorphine is an effective maintenance therapy in 
multiple dosage formulations – including daily or several times weekly – and is 
manufactured both singly as well as in a dual-formulation with naloxone to further 
prevent diversion efforts [67].  Multiple previous studies have shown effect with 
buprenorphine maintenance therapy in various settings including outpatient primary care 
clinics [23, 68] and other research suggests its use as a cost-effective public health 
measure [69]. 
Buprenorphine maintenance treatment involves three major phases – 1) induction, 2) 
stabilization, and 3) maintenance.  In the induction phase patients are given a “test dose” 
which is typically observed at the treatment facility.  This initial dose is usually 4mg and 
is given after a patient has been opiate-free for 12 to 24 hours and beginning to 
experience symptoms of opiate withdrawal.  Following verification that the patient 
tolerates the initial test dose, dose titration is begun rapidly to a dose of 16mg typically 
by day number two.  At this point the stabilization phase begins during which time the 
patient works with their clinician to achieve a dose at which they can greatly reduce or 
cease entirely opiate usage.  Psychosocial counseling and behavioral interventions are an 
important part of the stabilization phase.  Once the patient achieves a stable dosing 
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regimen and lack of continued cravings for opiate abuse the maintenance phase begins.  
During this phase the patient is maintained on their steady dose.  The length of this phase 
is contingent upon patient performance and comfort, and also the judgment of the 
clinician.  During the maintenance phase doses can continue to be adjusted and 
psychosocial and behavioral interventions are also often continued.   
Extended release naltrexone – a new medication-assisted treatment 
Naltrexone is a long-acting, full opioid-receptor antagonist utilized primarily in the 
treatment of alcohol and opioid dependence. Recent data [70] has shown a depot 
formulation of naltrexone as an effective treamtment modality for prevention of relapse 
in substance-dependent patients who have already undergone detoxification. Recently, 
Vivitrol, a depot, extended-release formulation of naltrexone, was approved in the United 
States for the treatment of opioid dependence; similar to buprenorphine, utilization of 
Vivitrol must follow detoxification from opioids. 
Given naltrexone‟s pure opioid antagonist properties there are no regulatory barriers to 
offering treatment. Additionally, the depot formulation comes in a monthly dosage. 
Given these properties, there is hope that Vivitrol may further expand access to 
medication-assisted treatments in patients previously unable to access resources due to 
the regulations and challenges surrounding methadone and buprenorphine. 
Tuberculosis screening in buprenorphine treatment programs 
Despite significant increases in access to medication-assisted treamtment over the last 40 
years, there remains significant stigma, regulatory barriers, and limited funding for such 
treatments.  While the overall number of patients receiving treatment has increased, 
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currently in the United States, only 15–20% of opioid-dependent patients have access to 
maintenance treatment [71, 72].  It is estimated that only approximately 200,000 patients 
have access to methadone [73], while in 2009 only approximately 600,000 patients had 
access to buprenorphine
1
.[74]. Currently depot naltrexone is too new to accurately 
estimate the number of patients on treatment. 
Given the great gap in medication-assisted treatment available to this population, there is 
a significant need for increased drug treatment opportunities.  In parallel, given the 
marginalization of this population from mainstream health care services, there is also 
need for enhanced primary care mechanisms to treat the medical co-morbidities of this 
population.  By creating innovative strategies to treat substance dependence in a primary 
care setting public health practitioners have already expanded opportunities for these 
patients [25, 27, 68, 75, 76].  Further expansion of substance abuse treatment programs 
integrated with primary care services can address both the continued disparity in drug 
treatment as well as medical care available to this population [5].   
Some treatment programs have begun to respond to this need by integrating primary care 
services with substance abuse treatment [23, 25, 27, 77-79].  These programs include 
screening and treatment of diseases commonly affecting substance users as well as 
induction and stabilization on medication-assisted treatments such as methadone and 
                                                          
1
 As of writing there are 20,180 buprenorphine-certified physicians in the United States. While no 
definitive numbers are yet available describing exactly how many patients have received/are receiving 
buprenorphine we know that during the 2009 year 640,000 individuals received a Suboxone/Subutex 
prescription, however length and number of refills of these prescriptions varied significantly. Through 
personal communication with Dr. Douglas Bruce of Yale University only “half or less [of these] are in 
„active treatment‟.”  
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buprenorphine [27, 44, 80-82].  Further, such programs are situated and conducted in 
ways more amenable to the specific needs of this population [5, 27].   
As previously discussed, a key component of health services for this population must 
address the increased prevalence of infectious diseases such as tuberculosis, HIV and 
viral hepatitis.  In examining these programs with an eye towards tuberculosis control, 
methadone maintenance treatment programs in particular have successfully incorporated 
tuberculosis screening.  Additionally, these programs also include further linkage to 
directly observed preventive therapy for those requiring tuberculosis treatment [81-84].  
Methadone treatment guidelines in the United States, as well as recommendations from 
the World Health Organization and Center for Disease Control and Prevention support 
the continued usage of such programs as evidence-based and cost-effective [51, 82] 
means of detecting and treating tuberculosis among opioid-dependent patients [85, 86]. 
Because of buprenorphine‟s liberalized regulatory framework and its consequent 
availability to the primary-care practitioner, buprenorphine maintenance treatment has the 
potential to greatly increase the availability of opiate-replacement therapy to those 
currently without access.  Further, if substance abuse treatment is coupled with primary 
care services, such expansion into the primary care setting also has the dual benefit of 
enhancing access for this population to ancillary services such as tuberculosis screening 
[87].  Regulations for methadone treatment programs, including recommendations for 
ancillary services offered, are well-founded after over 40 years of use in the clinical 
setting.  However, as standards of care for buprenorphine treatment continue to evolve, 
policy recommendations for associated clinical services, such as tuberculosis screening 
via tuberculosis skin testing, do not yet exist, nor is there data to support or refute such 
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policies.  Further, such programs are important to enhance treatment of both latent and 
active tuberculosis in this patient population and inform the development of further 
linkages to care for both isoniazid preventive therapies – for latent tuberculosis – as well 
as treatment programs for active infections including directly observed therapy programs.  
For this reason, we have examined the need and feasibility for implementation of a 
tuberculosis screening program in the setting of a buprenorphine treatment program.  
This research compares the prevalence of tuberculosis skin testing positivity among 
matched clients contemporaneously enrolled in buprenorphine and methadone treatment 
programs within inner-city New Haven, Connecticut. The treatment program described is 
the first mobile, community-based model for buprenorphine treatment and will also be 
discussed [88].   
Statement of Purpose 
While buprenorphine has been studied since the 1970s, strategies for optimizing 
buprenorphine maintenance treatment programs to provide associated primary care 
services for this population continue to be assessed and revised. This study will address 
the particular issue of tuberculosis screening in buprenorphine treatment programs.   
While the correlation between opiate addiction and tuberculosis infection has been well 
documented, and there are established international guidelines for tuberculosis screening 
in methadone programs, there has been to date no published investigation on the 
feasibility and efficacy of tuberculosis screening incorporated into buprenorphine 
programs.  Using the cohort of buprenorphine treatment patients here described, this 
study will compare positive rates of tuberculin skin testing to a contemporaneous and 
geographically similar matched cohort of methadone maintenance treatment patients.  
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Cohort averages as well as sub-group analysis will be described.  Implications for the 
need and practicality of such tuberculosis screening in buprenorphine maintenance 
treatment programs will be discussed. 
Hypotheses 
1. The prevalence of positive tuberculin skin tests in a buprenorphine treatment 
program will be similar to a contemporaneous and matched cohort of methadone 
treatment patients. 
2. It is possible to provide effective tuberculosis screening in the setting of a 
buprenorphine treatment program 
Aims of Research 
1. To evaluate the prevalence of positive tuberculin skin tests in contemporaneous, 
matched cohorts of buprenorphine and methadone maintenance treatment patients  
2. To assess the feasibility of implementing a tuberculosis screening program in a 
buprenorphine maintenance treatment program 
Methods 
Study Design 
A cross-sectional analysis of a retrospective cohort study was conducted to compare the 
prevalence of tuberculin skin test positivity between patients enrolled in the country‟s 
first mobile, community-based buprenorphine stabilization and induction program to 
contemporaneous patients enrolled in a nearby methadone maintenance treatment 
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program.  Both treatment-derived study groups were from the city of New Haven, 
Connecticut and were matched across four criteria. 
Ethical approval 
This study was approved through the Yale University School of Medicine‟s Human 
Investigation Committee (HIC# 27630). 
Site Descriptions 
New Haven, Connecticut 
New Haven is a moderate-sized, post-industrial, city of approximately 130,000 with a 
wide socioeconomic diversity.  Yale University is located in New Haven, however New 
Haven is also home to significant populations of African American and Latino American 
populations.  The “town-gown” relations between the former and latter are stark and 
socioeconomic, political and health inequities are significant.  Unemployment and 
poverty, substance abuse (including a high degree of injecting drug use), HIV and mental 
illness have made a deep impact upon the city.   
Community Health Care Van  
The Community Health Care Van (CHCV) is a 36-foot mobile medical facility that 
provides health services in parallel to a needle-exchange program in New Haven, 
Connecticut.  The CHCV provides health services five days per week throughout four 
neighborhoods in the New Haven area.  While some areas of New Haven are quite 
affluent, the neighborhoods the CHCV serves are disproportionately affected by poverty, 
substance abuse, HIV, Hepatitis C, and mental illness.  The CHCV provides a variety of 
basic treatment and preventive health services including basic medical care (as provided 
by a nurse practitioner/physician‟s assistant), screening for sexually transmitted 
infections, tuberculosis, and HIV, directly observed HIV therapy, referral to drug 
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treatment facilities and case management services, and buprenorphine induction and 
stabilization treatment for opioid-dependent patients.  The CHCV operates with the 
express goal of offering health services to marginalized populations within the New 
Haven area in a manner which enables patients to effectively access these services.  The 
focus of this research is in particular on the CHCV‟s provision of buprenorphine 
induction and stabilization services and the concurrent screening for tuberculosis in this 
population [44, 89]. 
The CHCV was first developed in 1991 when it operated out of an 18-foot van and 
provided services only one day per week.  Services expanded to two days per week in 
1994, offering HIV counseling and testing, social work referrals and acute medical care.  
The van expanded to its current form in 1996 and now has two examination rooms and 
one counseling room.  Service provision has been continually expanded both in scope and 
in number of days offered since 1996.  Clinical care and medications donated through 
affiliated programs are provided free of charge to uninsured patients and all patients are 
offered referral services to local and regional health facilities as indicated [88, 89].  The 
clientele of the CHCV are diverse yet all from particularly disadvantaged and 
underserved backgrounds.  Over 35% are previous or current injecting drug users, 
approximately 70% are unemployed, 27% reported previous or current commercial sex 
work, and 26% had been in jail or prison in the 6 months prior to CHCV engagement 
[89]. 
Key components of the CHCV‟s buprenorphine treatment program include rapid 
initiation of opioid-replacement therapy, surveillance for associated infectious diseases 
and/or psychiatric co-morbidities, and street-level case management services.  An 
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additional critical component of the CHCV program is its harm reduction approach to 
complicated patients with multiple health and psychosocial co-morbidities.  With 
particular regard to the buprenorphine treatment program, if patients are effectively 
taking their buprenorphine and engaging in parallel psychosocial and behavioral 
counseling, other high-risk behaviors such as continued illicit substance abuse (e.g. crack 
cocaine) are tolerated and not addressed punitively (e.g. discharge from the 
buprenorphine program or judgement/stigmatization from health care providers at the 
CHCV).  Such harm-reduction techniques have been well established as effective means 
of treating substance abuse and retaining patients in active engagement with health 
providers.  This approach helps to maintain patients engaged in health services and 
counseling creating an environment in which further behavioral modification and general 
health improvement may occur [28].   
While such an approach has proven effective in enhancing the provision of health 
services to this marginalized population, it also entails certain challenges in 
implementation.  This patient population frequently has difficulty in maintaining set 
appointments thus requiring significant flexibility in staffing and time allocation for 
counseling sessions.  The CHCV program was developed with the intention of ensuring 
therapeutic encounters at the time the patient presented for treatment, in direct contrast to 
the standard health care system which is centered on clinician-set appointments.  This 
operations model requires staff to be flexible to see patients that they have not previously 
seen, at times they had not expected patients to arrive, yet also ensures patients are 
engaged in health services in a manner that their challenging life circumstances can 
accommodate.  All staff accordingly are connected via cell phones and able to 
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communicate with other counselors and health care providers and are additionally co-
located within the same mobile unit to allow one staff member to assist another when 
patients unexpectedly arrive and/or require more attention than typically expected.  
Providing health services in this fashion is time-intensive and costly, however by 
adopting a harm-reduction approach the CHCV has effectively provided health services 
to a population previously marginalized from the health care system and ultimately 
enhanced the health status of this population [27, 44, 89]. 
Buprenorphine Maintenance Treatment Subjects  
Buprenorphine treatment subjects were derived from Project BEST – Buprenorphine 
Entry into Substance abuse Treatment – which is the first mobile, community-based, 
buprenorphine induction and stabilization program in the United States [44].  Project 
BEST operates out of the CHCV as described above and is funded by the Substance 
Abuse and Mental Health Services Agency (SAMHSA).  All patients enrolling in Project 
BEST underwent induction and treatment in accordance with Treatment Improvement 
Protocol 40 guide-lines [90].   
Criteria for inclusion in buprenorphine treatment included: 
1. fulfilling DSM-IV criteria for opioid dependence; 
2. no previous uncontrolled benzodiazepine abuse; 
3. hepatic transaminase values less than five times the upper limit of normal; and 
4. a negative pregnancy test for women of child-bearing age. 
Induction to Project BEST consisted of a standardized protocol over a two-day period.  
On the first day patients received 8mg divided into two doses over 1 to 2 hours, and 
16mg on the second day.  In addition to buprenorphine patients also received evidence-
based drug treatment counseling.  Manualized counseling included an initial four weeks 
of motivational enhancement therapy and an additional eight weeks of cognitive 
Page | 27  
 
behavioral therapy [91].  Patients enrolled in the program also received weekly urine 
immunoassay tests for opiates, cocaine, THC, methadone and/or benzodiazepines.  
Following the initial 12 weeks of treatment patients returned for urine toxicology and 
counseling at a frequency determined by the clinician, per the patient‟s perceived stability 
and progress in the program [88].  
Project BEST utilized a single pharmacy for all buprenorphine provision.  Early in 
treatment patients were prescribed only one-week supplies of buprenorphine which was 
intended to last from one counseling appointment to the next.  Prescriptions were written 
for a one-week bottle with 3 refills however patients were required to show up to 
counseling sessions in order to fill the refill.  The latter was accomplished by never 
providing patients with an actual prescription but instead a voucher.  This voucher 
required that both the patient and the counselor sign it at the time of the counseling 
session, and also emboss it with a program seal.  The pharmacy ensured that only 
vouchers – and never prescriptions – that were doubly signed and embossed, were filled.  
Through this mechanism Project BEST was able to ensure that all buprenorphine 
treatment was accompanied by a minimum of 12 weeks counseling as patients began the 
program [88]. 
In addition to buprenorphine maintenance treatment, all Project BEST enrollees are 
routinely screened for HIV, tuberculosis, hepatitis B and C, and sexually transmitted 
diseases [44, 92].  Hepatitis B vaccination is also provided for eligible participants [93].  
All Project BEST participants also undergo health surveys to collect relevant information 
about their past and current health status, substance abuse behavior, socioeconomic and 
demographic information.  These surveys include the Addiction Severity Index (ASI) 
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[94], the Structured Clinical Interview for DSM-IV (SCID) [95], the CHCV Short and 
Long forms, and the Project BEST Supplemental Survey [88], and are conducted at 
induction as well as periodically thereafter.  In addition to the surveys documented, 
subjects enrolled in Project BEST provided informed consent to access all medical 
records from one year prior to induction to five years following enrollment.  
Methadone Maintenance Treatment Subjects 
To investigate the concurrent prevalence of tuberculosis among methadone maintenance 
patients in the area, characteristics from Project BEST participants were matched to 
methadone patients enrolled at The APT Foundation in New Haven, Connecticut.  The 
APT Foundation (http://www.aptfoundation.org/) runs New Haven‟s largest (2,000 
patients) methadone maintenance treatment program and has been providing treatment to 
substance users for over 40 years.  Through their methadone treatment program, all APT 
Foundation clients are routinely screened for tuberculosis and mental illness.  Additional 
screening for hepatitis B and C is performed if deemed clinically appropriate, and HIV 
testing is voluntary.  Finally, all entrants to The APT Foundation‟s methadone 
maintenance treatment program provide informed consent for medical chart review 
extraction involving de-identified data. 
Inclusion criteria for methadone maintenance treatment at The APT Foundation includes 
1) adults over the age of 21 years old, 2) fulfillment of DSM-IV criteria for opiate 
addiction of greater than one year in duration, and 3) one previous treatment failure.  
Pregnant women under 21 years old are admitted on a case-by-case basis at the discretion 
of clinicians.  The APT Foundation serves a wide catchment area including cities 
surrounding New Haven such as Milford, Old Saybrook and Wallingford [96]. 
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Definitions 
In collecting data from Project BEST and The APT Foundation, medical record 
formatting was distinct between the two groups, and therefore, reconciliation of selected 
variables is required.  The level of previous education was categorized differently in the 
two study groups – for Project BEST patients, the number of months of education was 
reported, with 144 months being equivalent to having completed a high-school education.  
Conversely however, for APT Foundation patients education data was recorded only by 
the number of years of education completed.  Secondly, to assess the substance of abuse 
preferred by each patient, data from both groups was compiled according to whether 
patients had reported a given substance as their primary, secondary, or tertiary substance 
of choice.  Substances that were listed but not classified as primary, secondary, or 
tertiary, were not included in data analysis.  Last, to evaluate the psychiatric co-
morbidities of patients, including previous and current treatment histories, all enrollees 
were defined to have an a priori diagnosis of substance abuse.  Additional psychiatric co-
morbidities were defined if, in addition to their substance abuse treatment, patients were 
also engaged in outpatient psychiatric care, with or without prescription medications, 
prior to buprenorphine or methadone maintenance treatment enrollment.  This psychiatric 
outpatient data was reported through the Addiction Severity Index survey for Project 
BEST clients and through a standardized admission form for all patients at The APT 
Foundation. 
Data Sources 
Data for Project BEST buprenorphine and APT Foundation methadone maintenance 
treatment subjects were compared for enrollees from January 1
st
, 2005 to June 30
th
, 2007.  
Subjects from Project BEST were matched to clients at The APT Foundation on four 
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criteria including age, gender, race, and previous history of crack or cocaine use.  
Utilizing these criteria allowed for the evaluation of factors previously associated with 
tuberculin skin test positivity [97, 98] in comparing patients in Project BEST 
buprenorphine treatment to those in The APT Foundation‟s methadone program.  Chart 
review was performed by author RS on 190 patients from the buprenorphine and 
methadone treatment matched groups using a uniform data extraction instrument.  The 
data extraction instrument was developed using the Teleform software package [99] 
enabling hand-written chart-review data to be easily translated into Microsoft Excel 
databases for analysis.  Clinical data, including previous and enrollment tuberculin skin 
test results, was extracted retrospectively via chart review in accordance with HIC 
#27630.  All data was subsequently uploaded to databases stored at The Yale AIDS 
Program at 135 College St, Suite 323, where it was kept under password protection in 
accordance with HIC #27630 protocol. 
Tuberculin skin test results were unavailable for 15 subjects in the Project BEST cohort 
and 19 in The APT Foundation cohort due to insufficient record keeping at the study 
sites.  These subjects were excluded from the final data analysis and are not exhibited in 
the results tables.  Ultimately data collection resulted in 175 and 171 subjects in the 
Project BEST and The APT Foundation study groups, respectively.  To account for the 
missing tuberculin skin testing data, each group was reassessed.  This re-evaluation 
verified that characteristics set by the original matching criteria were retained.  No 
statistically significant differences were found in this re-evaluation. 
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Data Analysis 
The prevalence of tuberculin skin test positivity and comparison of demographic and 
substance use characteristics were compared between buprenorphine and methadone 
treatment study groups using two-sided chi-square tests (alpha = .05).  Bivariate 
associations with the primary outcome (tuberculin skin test positivity) were calculated to 
determine variables that could be included into the final multiple logistic regression 
model for predicting skin test positivity.  The Akaike information criterion (AIC) was 
used to assess model fit – a lower AIC value indicates a better balance of parsimony and 
clarification of variance.  A p-value <0.20 was used to enter and leave the regression 
model.  The two-sided Wald‟s test (alpha = .05) was used to assess significance of each 
of the variables.  All statistical analyses were performed at The Yale AIDS Program 
using SAS, version 9.1.3 (SAS Institute, Cary, NC). 
Results 
The demographic and health characteristics of the two comparison groups, described in 
Table 1, did not differ statistically.  Though the two groups did not differ on the primary 
outcome (9% in both groups were tuberculin skin test positive), the buprenorphine 
treatment group contained twice as many (6% vs. 3%) “new” positive skin test results, 
with the opposite found in the methadone treatment group where twice as many (6% vs. 
3%) were “previously detected” positive skin tests.  Thus, 10 (62.5%) of the 16 
buprenorphine treatment subjects and 5 (33.3%) of the 15 methadone treatment subjects 
had “new” positive skin test results and trended toward significance (p = .10).  
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Though not significant, there was a trend toward higher levels of education in the 
buprenorphine treatment group with 27% having completed education beyond high 
school compared to 19% in the methadone treatment group (p =.07).  Over a third of all 
patients in both groups (36% of buprenorphine vs. 34% of methadone treatment) met 
criteria for an Axis I disorder, thus qualifying as having a co-morbid mental illness in 
addition to opioid-dependence. 
There were, however, significant differences between the two groups in their reported 
substance use preferences (Table 2). Enrollees in buprenorphine treatment were 
statistically more likely to report secondary preferences for alcohol (30% vs. 8%, p < 
.0001) and benzodiazepines (8% vs. 3%, p = .038) than their methadone treatment 
counterparts, while the latter expressed higher preferences for heroin (91% vs. 71%, p < 
Page | 33  
 
.0001) and cocaine (69% vs. 26%, p < .0001).  
Unadjusted and adjusted analyses are presented in Table 3.  Unadjusted analysis 
illustrated a significant association between tuberculin skin test positivity and black race 
(OR = 2.72).  The adjusted analysis indicated statistically significant higher associations 
between skin test positivity and blacks (AOR = 3.53, 95% CI = 1.28–9.77), Hispanics 
(AOR = 3.11, 95% CI = 1.12–8.60) and higher education status (AOR = 3.01, CI = 1.20–
7.53).  All other associations were non-significant.  




The purpose of this study was to evaluate the prevalence of tuberculin skin test positivity 
in a buprenorphine treatment group as compared to a similar and contemporaneous 
methadone treatment cohort.  Buprenorphine is a relatively new treatment modality for 
opiate-dependent patients and accordingly best practices surrounding the implementation 
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of such programs are not fully understood.  Given the pre-existing guidelines that all 
methadone treatment patients should be screened for tuberculosis, yet the lack of 
evidence supporting or refuting similar guidelines for buprenorphine treatment programs, 
the data from our study can be used to inform policy and the guidelines surrounding 
substance abuse treatment programs. 
To our knowledge, this is the first study examining the prevalence of tuberculin skin test 
positivity in a group of patients receiving buprenorphine treatment.  Data from this study 
illustrate a similar prevalence of 9% in new enrollees in both methadone and 
buprenorphine maintenance treatment programs in the same community.  In light of the 
current recommendations that all clients entering methadone treatment programs be 
screened for tuberculosis, our findings suggest that similar screening practices are 
warranted for patients initiating buprenorphine treatment.   
In particular, such screening is important as buprenorphine may be reaching a different 
target of opioid-dependent patients in community settings as evidenced in our study by 
the differing poly-substance use profiles.  Though not reaching statistical significance, 
the trend that the buprenorphine program identified more “new” positive skin tests 
requires further investigation, and again suggests that buprenorphine may be reaching a 
group of opioid-dependent patients with different risk profiles.  Data found in our study 
suggesting differing characteristics between methadone and buprenorphine treatment 
patients is consistent with previous research [77].  Nonetheless, irrespective of the 
different sociodemographic and/or risk profiles highlighted by this and previous data, 
similar prevalence of skin test positivity still suggests that buprenorphine enrollees also 
require tuberculosis screening at entrance.  
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Similar to previous studies, these findings additionally suggest higher positive 
tuberculosis prevalence among racial and ethnic minorities – specifically blacks and 
Hispanics [100].  Such results highlight the different health risks of people of color in the 
United States and confirm not only the need for identifying those at highest risk for 
tuberculosis, but ensuring that they are screened and prophylactically treated. 
Paradoxically in this study, higher education, often a marker of higher socioeconomic 
status, was associated with a positive tuberculin skin test.  To our knowledge, this has not 
been previously demonstrated among treatment-seeking opioid-dependent populations.  
A potential explanation of this result is that those with higher levels of education who 
were skin test positive were those that had formerly worked within congregate settings, 
such as nursing homes, hospitals or even prisons, where tuberculin skin test conversions 
would be expected.  An alternative explanation of these data could be that those 
Hispanics with higher education were not U.S.-born, but came to the United States in 
search of financial opportunities and had been previously exposed to tuberculosis within 
their home or endemic within their country.  Given a higher previous educational history 
we could conjecture that such persons were more able to immigrate to the United States 
in search of more gainful employment opportunities.  We assessed the latter relationship, 
however, and there was no significant interaction. Further studies are warranted to more 
accurately characterize this population, to confirm or refute our findings, and to better 
establish the relationship between higher education and tuberculin skin test positivity.  
Of note, our study offers implications for the development of enhanced linkages to 
tuberculosis treatment strategies for the buprenorphine patient population.  Previously it 
has been shown that isoniazid treatment offered in parallel to methadone maintenance 
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therapy programs is both effective [101] and cost-effective [102], with innovative 
treatment models enhancing adherence [103, 104].  In part, this is due to the increased 
structured environment that methadone treatment programs offer with consistent and 
regular follow-up enabling parallel directly observed isoniazid therapy.  However, in 
contrast, due to the more rapid rate at which buprenorphine maintenance treatment 
patients receive at-home medication privileges, such consistent structure is typically not 
available. Thus, in parallel to implementing screening programs for tuberculosis with 
buprenorphine maintenance treatment, consideration should also be paid to alternative 
interventions to ensure adequate treatment success on tuberculosis treatment.  Previous 
strategies to enhance adherence [103, 104] may be instructive yet further research will be 
required to optimize treatment success. Notably, our data also offers potential 
implications in the international arena. While medication-assisted treatments are limited, 
if not non-existent, in many countries outside of the United States, increasingly other 
nations are developing substance-dependence treatment programs utilizing medication-
assisted therapies. Data from developed country models such as the long-standing 
programs in the UK [105] have offered critical insight on the development of newer 
programs in countries such as Malaysia or the Ukraine. Both of the latter examples have 
significant HIV epidemics largely fueled by injecting drug use, and therefore the 
implementation of safe, effective and cost-effective substance-dependence programs will 
be critical to their public health systems [106, 107]. Our data offers an important insight 
for such programs, especially those in which medication-assisted treatment will address 
large burdens of HIV and associated conditions such as tuberculosis. Further data from 
studies such as our own will help to inform these best-practices and thereby enhance the 
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evidence base for developing programs. By adopting tuberculosis screening in parallel 
with the implementation of methadone and/or buprenorphine maintenance treatment 
programs, public health investments in newly developing programs will be more effective 
and cost-effective.  
Notably, this study has several important limitations. The sample size of the 
buprenorphine treatment program, while growing, remains relatively small.  Furthermore, 
recommendations stemming from these data are specific to the New Haven community 
context, and given the paucity of existing buprenorphine treatment programs, it is as yet 
unclear to what extent our data are generalizeable to the larger opioid-dependent patient 
population. Additionally, the CHCV is a particular buprenorphine setting that may further 
limit the degree of generalizability of our data. Finally, with particular regard to analysis 
of psychiatric co-morbidities, we recognize survey data as utilized in this study are less 
reliable than validated diagnostic indices.  As a result, we suspect that we have likely 
underestimated the overall burden of psychopathology in our study groups.  
Despite these limitations, these data provide preliminary but compelling support for 
incorporating tuberculosis screening into buprenorphine treatment programs.  Such 
inclusion provides increased potential for detection of latent tuberculosis and enhances 
access to onsite primary care services for an already marginalized patient population. 
Increased detection of latent tuberculosis may, therefore, result in increased access to 
treatment due to engagement in continuity of care.  This is particularly true because of 
buprenorphine‟s availability within the primary care setting where regular tuberculin skin 
test screening would facilitate linkage to treatment.  Finally, our experience 
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implementing this screening program has illustrated that it is a practical model that can be 
considered for other buprenorphine treatment programs.   
As research continues to define standards of care for buprenorphine maintenance 
treatment, other mechanisms to ensure increased access to primary care services for 
opioid-dependent patients, in particular targeting those co-morbidities known to exist in 
this population, should remain a priority. 
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